YOU MATTER.
Upcoming Events
Charlotte Kidney Cancer Support Group – Holiday Luncheon
November 26 @ 1:00 pm - 3:30 pm
Publications
0
%
5-Year Survival Rate Percentage increase from 2007 through 2013
0
Estimated new cases in the US, this year
0
Estimated Deaths in the US, this year
0
People are living with kidney and renal pelvis cancer, according to NCI SEER data from 2014
Evaluate your treatment options and make decisions
From the Pressroom
News from Kidney Cancer Association This feed has been created by Kidney Cancer Association
-
MDACC 2018: Debate: What is the Best Front-Line...
on November 12, 2018 at 6:09 pm
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 […]
-
MDACC 2018: Debate: What is the Best Salvage...
on November 12, 2018 at 6:02 pm
Dr. Msaouel discusses the best treatment options after failure of immune checkpoint inhibition.11/12/2018 […]
-
MDACC 2018: Debate: Is There Still a Role for...
on November 12, 2018 at 5:57 pm
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 […]
YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.
Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers.
MDACC 2018: Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn’t?
MDACC 2018 when to choose chemotherapy versus targeted therapy in non-clear cell histology, Anti-VEGF TKIs, Sunitinib, Pazopanib, Axitinib, Cabozanitinib, first line or salvage options in non-clear cell RCCs with Sunitinib being the preferred option based on the ASPEN, ESPN, and RECORD-3 trial.
urotoday.com
Immunotherapy/TKI Combinations in Advanced RCC
Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.
targetedonc.com
Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combo prolongs progression-free survival compared with sunitinib as first-line therapy in patients with advanced RCC
renalandurologynews.com
1 day ago
The latest Cancer News Daily! https://t.co/leRUdnlPnX Thanks to @cleaneatscarrie @SSSandied53 @DHUNTtweets #cancer #breastcancer
The latest Cancer News Daily! https://t.co/leRUdnlPnX Thanks to @cleaneatscarrie @SSSandied53 @DHUNTtweets #cancer #breastcancer
The latest Cancer News Daily! https://t.co/leRUdnlPnX Thanks to @cleaneatscarrie @SSSandied53 @DHUNTtweets #cancer #breastcancer
— Kidney Cancer (@KidneyCancer) November 13, 2018
1 day ago
Our 2017 YIA winner Dr. Pavlos Msaouel is doing great work in #KidneyCancer research! In this article, he discusses chemotherapy vs. targeted therapies. https://t.co/Fl4mNWwmmX
Our 2017 YIA winner Dr. Pavlos Msaouel is doing great work in #KidneyCancer research! In this article, he discusses chemotherapy vs. targeted therapies. https://t.co/Fl4mNWwmmX
Our 2017 YIA winner Dr. Pavlos Msaouel is doing great work in #KidneyCancer research! In this article, he discusses chemotherapy vs. targeted therapies. https://t.co/Fl4mNWwmmX
— Kidney Cancer (@KidneyCancer) November 12, 2018
2 days ago
The latest Cancer News Daily! https://t.co/QKRNMKaRAO Thanks to @krock955 @nells_belles @ecbwin #cancer #health
The latest Cancer News Daily! https://t.co/QKRNMKaRAO Thanks to @krock955 @nells_belles @ecbwin #cancer #health
The latest Cancer News Daily! https://t.co/QKRNMKaRAO Thanks to @krock955 @nells_belles @ecbwin #cancer #health
— Kidney Cancer (@KidneyCancer) November 12, 2018